First-line treatment in metastatic colorectal cancer: Important or crucial?

First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of care. In addition to chemotherapy, patients may receive either bevacizumab, an anti-vascular endothelial growt...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2017-10, Vol.84, p.363-366
Main Authors: Malka, David, Rotolo, Federico, Boige, Valérie
Format: Article
Language:English
Subjects:
5-Fluorouracil
Antibodies
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Biological effects
Camptothecin
Cancer
Chemotherapy
Clinical trials
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms
Comparative analysis
Epidermal growth factor
Epidermal growth factor receptors
Folinic acid
Humans
Immunoglobulins
Irinotecan
Metastases
Metastasis
Monoclonal antibodies
Organoplatinum Compounds
Oxaliplatin
Targeted cancer therapy
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of care. In addition to chemotherapy, patients may receive either bevacizumab, an anti-vascular endothelial growth factor (VEGF)-directed antibody, or (in RAS wild-type tumours) anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab). A decade has passed since the advent of these two classes of biological agents until the results of the two phase III studies comparing them to each other in combination with first-line chemotherapy.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2017.09.001